| Study |
|
Exclusion reasons |
Remarks |
Reference(s) |
|
|
study 101 dose finding, 2020
|
non randomized controlled trial
|
no control group
|
phase 1
|
Anderson EJ N Engl J Med 2020 Sep 29. 10.1056/NEJMoa2028436 Jackson LA N Engl J Med 2020 Nov 12;383(20):1920-1931. 10.1056/NEJMoa2022483
|
|
|
Montgomery, 2021
|
retrospective cohort
|
no control group
|
|
Montgomery J et al. JAMA Cardiol 10.1001/jamacardio.2021.2833
|
|
|
Ruddy, 2021
|
case series
|
no control group
|
|
Ruddy JA AIDS 2021 Sep 1;35(11):1872-1874. 10.1097/QAD.0000000000002945
|
|
|
Burns, 2022
|
-
|
no control group
|
|
Burns MD et al. medrxiv;2022.01.05.22268617v1 10.1101/2022.01.05.22268617
|
|
|
Kawasuji, 2022
|
-
|
no control group
|
|
Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433
|
|
|
Falsey, 0
|
-
|
no control group
|
|
Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468
|
|
|
BioNTech phase 2 (Walsh), 2020
|
randomized controlled trial
|
no clinically relevant endpoint
|
phase 1-2 ; dose-escalation : 13 groups of 15 participants
|
|
|
|
Moderna preclinical (Corbett), 2020
|
randomized controlled trial
|
other
|
|
Corbett KS N Engl J Med 2020 Oct 15;383(16):1544-1555. 10.1056/NEJMoa2024671
|
|
|
Pfizer 16-25 years phase 3, 0
|
randomized controlled trial
|
other
|
very preliminary results from a press release
|
|
|
|
Ou, 2021
|
case series
|
other
|
safety and reactogenicity, no immunogenicity
|
Ou MT Transplantation 2021 Apr 9. 10.1097/TP.0000000000003780
|
|
|
Molteni, 2022
|
-
|
other
|
modelling study
|
Molteni E et al. medrxiv;2022.03.13.22272176v1 10.1101/2022.03.13.22272176
|
|
